Keros Therapeutics: A Biotech Stock on the Move Amid Strategic Review and Rights Plan

In a move that’s got investors buzzing, Keros Therapeutics (NASDAQ: KROS) has announced a review of…

Sage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround Story

Sage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround Story #Sage #Therapeutics #Speculative…

Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock (NASDAQ:AKRO)

This article was written by Follow Avisol Capital Partners is made up of a team of…

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout #Janux #Therapeutics #Buying #Promising #Pipeline…

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation…

OrbiMed Advisors LLC purchases $10 million in Edgewise Therapeutics stock

OrbiMed Advisors LLC purchases $10 million in Edgewise Therapeutics stock#OrbiMed #Advisors #LLC #purchases #million #Edgewise #Therapeutics…

Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292

Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292#Bicycle #therapeutics #CTO #Michael #Skynner #sells #shares #worth

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal #Sangamo #Therapeutics #Scope #Eli…

Pliant Therapeutics: An Activist On Deck

Pliant Therapeutics: An Activist On Deck #Pliant #Therapeutics #Activist #Deck

Zevra Therapeutics: Mixed Feelings On Miplyffa Approval

Zevra Therapeutics: Mixed Feelings On Miplyffa Approval #Zevra #Therapeutics #Mixed #Feelings #Miplyffa #Approval

Corcept therapeutics officer sells $20.2 million in stock

Corcept therapeutics officer sells $20.2 million in stock#Corcept #therapeutics #officer #sells #million #stock

Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ET Company…

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study…

Corcept Therapeutics: A Stock on the Rise, But Is It a Buy?

As an investor, it’s always exciting to see a stock surge in value. And Corcept Therapeutics…

Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade)

Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade) #Summit…

Soleno Therapeutics: A Breakthrough in Rare Disease Treatment

The biotech world is buzzing with excitement as Soleno Therapeutics (SLNO) has just received FDA approval…

CRISPR Therapeutics Set To Reach Previous Heights

CRISPR Therapeutics Set To Reach Previous Heights #CRISPR #Therapeutics #Set #Reach #Previous #Heights

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript #Atossa #Therapeutics #ATOS #Earnings #Call #Transcript

Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts

Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts #Verve #Therapeutics #HeFH…

ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025

ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 #ADC #Therapeutics…

Monte Rosa Therapeutics: Exercise Extreme Caution

Monte Rosa Therapeutics: Exercise Extreme Caution #Monte #Rosa #Therapeutics #Exercise #Extreme #Caution

Aquestive Therapeutics: Not For Me, But Attractive

Aquestive Therapeutics: Not For Me, But Attractive #Aquestive #Therapeutics #Attractive